Ketoconazole enantiomer in humans
Treatment of patients with the 2S,4R ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates is useful for reducing systemic inflammation and cholesterol levels and improving glycemic control.
1. A method of reducing C-reactive protein levels in a patient in need of such reduction, comprising administering a daily dose of a ketoconazole composition comprising 200 mg to 600 mg of a 2S,4R ketoconazole enantiomer substantially free of the 2R,4S ketoconazole enantiomer to said patient.
2. The method of claim 1 , further comprising identifying or diagnosing the patient as having elevated plasma C-reactive protein and in need of reduction of systemic inflammation.
3. The method of claim 2 , wherein the patient has a plasma C-reactive protein level greater than 3.0 mg/L.
4. The method of claim 2 , wherein the patient has a plasma C-reactive protein level greater than 5.0 mg/L.
5. The method of claim 1 , wherein the patient is diabetic.
6. The method of claim 1 , wherein the patient is diagnosed with metabolic syndrome.
7. The method of claim 1 , wherein the daily dose of the ketoconazole composition is 200 mg to 400 mg of the 2S,4R ketoconazole enantiomer.
8. The method of claim 1 , wherein the ketoconazole content of the composition is more than 98% of the 2S,4R ketoconazole enantiomer.
9. The method of claim 1 , wherein the patient has elevated C-reactive protein levels in plasma.
10. A method of reducing systemic inflammation in a patient in need thereof comprising administering a daily dose of a ketoconazole composition comprising 200 mg to 600 mg of 2S,4R ketoconazole enantiomer substantially free of the 2R,4S ketoconazole enantiomer to said patient.
11. The method of claim 10 , wherein the daily dose of the ketoconazole composition is 200 mg to 400 mg of the 2S,4R ketoconazole enantiomer.
12. The method of claim 10 , wherein the ketoconazole content of the composition is more than 98% of the 2S,4R ketoconazole enantiomer.
13. The method of claim 10 , wherein the patient has elevated C-reactive protein levels in plasma.
14. The method of claim 10 , further comprising identifying or diagnosing the patient as having elevated plasma C-reactive protein and in need of reduction of systemic inflammation.
15. The method of claim 10 , wherein the patient has a plasma C-reactive protein level greater than 3.0 mg/L.
16. The method of claim 10 , wherein the patient has a plasma C-reactive protein level greater than 5.0 mg/L.
17. The method of claim 10 , wherein the patient is diabetic.
18. The method of claim 10 , wherein the patient is diagnosed with metabolic syndrome.